Zevra Therapeutics — Third Quarter 2026 Earnings Summary

Zevra Therapeutics reported third-quarter 2026 net revenue of $37.8 million, representing a 45% increase from the same period in 2025, driven primarily by $34.0 million in sales of its product MIPLYFFA. The company achieved a net income of $19.2 million for the quarter, supported by a strong cash position of $270.9 million as of September 30, 2026. Operational highlights included the enrollment of six additional patients in the Phase 3 DiSCOVER trial for celiprolol and the receipt of 13 new prescription enrollment forms for MIPLYFFA in the U.S. Additionally, Zevra anticipates filing a supplemental New Drug Application for MIPLYFFA in infants under 24 months of age during the first quarter of 2027.